John Newell-Price
Overview
Explore the profile of John Newell-Price including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
4474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isand K, Arima H, Bertherat J, Dekkers O, Feelders R, Fleseriu M, et al.
Eur J Endocrinol
. 2025 Feb;
192(3):R17-R27.
PMID: 39973025
The objective of this study was to establish recommendations for thromboprophylaxis in patients with endogenous Cushing's syndrome (CS), addressing the elevated risk of venous thromboembolism (VTE) associated with hypercortisolism. A...
2.
Fleseriu M, Pivonello R, Newell-Price J, Gadelha M, Biller B, Auchus R, et al.
Pituitary
. 2025 Jan;
28(1):22.
PMID: 39863744
Purpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease. Methods: Pooled analysis of two Phase III osilodrostat...
3.
Nieman L, Castinetti F, Newell-Price J, Valassi E, Drouin J, Takahashi Y, et al.
Nat Rev Dis Primers
. 2025 Jan;
11(1):4.
PMID: 39848955
Cushing syndrome (CS) is a constellation of signs and symptoms caused by excessive exposure to exogenous or endogenous glucocorticoid hormones. Endogenous CS is caused by increased cortisol production by one...
4.
Newell-Price J, Fleseriu M, Pivonello R, Feelders R, Gadelha M, Lacroix A, et al.
J Endocr Soc
. 2024 Nov;
9(1):bvae201.
PMID: 39610378
Purpose: To assess whether simultaneous normalization of late-night salivary cortisol (LNSC) and mean urinary free cortisol (mUFC) in patients with Cushing disease treated with osilodrostat is associated with better clinical...
5.
Newell-Price J, Drummond J, Gurnell M, Levy M, McCormack A, Cooper D, et al.
J Clin Endocrinol Metab
. 2024 Aug;
110(2):e506-e514.
PMID: 39148427
Investigation and management of hypotonic polyuria is a common challenge in clinical endocrinology. The 3 main causes, recently renamed to arginine vasopressin deficiency (AVP-D, formerly central diabetes insipidus), arginine vasopressin...
6.
Rees D, Merke D, Arlt W, Brac de la Perriere A, Linden Hirschberg A, Juul A, et al.
Endocr Connect
. 2024 Jun;
13(8).
PMID: 38934378
Background: Prednisolone and prednisone are recommended treatment options for adults with congenital adrenal hyperplasia (CAH); however, there is no randomised comparison of prednis(ol)one with hydrocortisone. Design: Six-month open-label randomised phase...
7.
Kelsall A, Newell-Price J
J Endocr Soc
. 2024 May;
8(7):bvae094.
PMID: 38803555
No abstract available.
8.
Debono M, Elder C, Lewis J, Fearnside J, Caunt S, Dixon S, et al.
NEJM Evid
. 2024 Feb;
2(2):EVIDoa2200182.
PMID: 38320034
BACKGROUND: Worldwide, adults and children are at risk of adrenal insufficiency as a result of adrenal suppression from use of anti-inflammatory glucocorticoids and opiates, as well as infectious diseases. The...
9.
Arshad M, Elder C, Newell-Price J, Ross R, Debono M
J Clin Endocrinol Metab
. 2024 Feb;
109(11):e2031-e2037.
PMID: 38298131
Context: Glucocorticoids suppress the hypothalamic-pituitary-adrenal (HPA) axis, resulting in tertiary adrenal insufficiency (AI). When weaning patients off glucocorticoids there is no consensus on whether to maintain patients on prednisolone or...
10.